EP0591486A1 - Action immunostimulante et par consequent antivirale des composes 4- 3-(aminosubst.)-2-hydroxypropoxy]-1,2,5-thiadiazol - Google Patents

Action immunostimulante et par consequent antivirale des composes 4- 3-(aminosubst.)-2-hydroxypropoxy]-1,2,5-thiadiazol

Info

Publication number
EP0591486A1
EP0591486A1 EP93907746A EP93907746A EP0591486A1 EP 0591486 A1 EP0591486 A1 EP 0591486A1 EP 93907746 A EP93907746 A EP 93907746A EP 93907746 A EP93907746 A EP 93907746A EP 0591486 A1 EP0591486 A1 EP 0591486A1
Authority
EP
European Patent Office
Prior art keywords
thiadiazole
hydroxypropoxy
butylamino
humans
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93907746A
Other languages
German (de)
English (en)
Inventor
Karin Elisabeth Peuschel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0591486A1 publication Critical patent/EP0591486A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Definitions

  • R is chlorine, ethyl, ethoxy, phenyl, morpholino, piperidino or hydroxypiperidino and R 'is -C (CH 3 ) 3 or -CH (CH 3 ) 2 , the pure optical isomers with an immuno-activating effect and the pharmacologically acceptable ones Salts of these compounds and the immune-activating effect of a pharmaceutical composition containing one of these compounds.
  • immune activation is defined here as facilitated activation of the immune system in the presence of foreign antigen.
  • the immune-activating effect arises on the one hand by blocking the inhibitory effect of the sympathetic nervous system on the immune system and on the other hand by blocking stress centers in the central nervous system ⁇ particular of the paraventricular nucleus of the hypothalamus, which presupposes the type of neuroimmune regulation or an analogue type found in humans, ie the control of the immune system by hypothalamic centers over two axes, firstly via the hypothalamoadrenocortical axis, secondly via the vegetative nervous system, especially the sympathetic nervous system.
  • Biochemical activation reactions of the immune system are enhanced by the elimination of the inhibitory effect of catecholamines in the presence of foreign antigen.
  • Suitable pharmacologically acceptable salts of these compounds are acid addition salts which are derived from inorganic acids, for example hydrochlorides, hydrobromides, phosphates or sulfates, or salts which are derived from organic acids, for example oxalates, lactates, malates, maleates, formates, acetates, Succinates, tartrates, salicylates, citrates, phenylacetates, benzoates, p-toluenesulfonates and other salts, such as those which provide relatively insoluble products which cause slow release of the active material, for example a 1, -T-methylene bis ( 2-hydroxy-3-naphthoate).
  • inorganic acids for example hydrochlorides, hydrobromides, phosphates or sulfates
  • organic acids for example oxalates, lactates, malates, maleates, formates, acetates, Succinates, tartrates, salicylates, citrates,
  • the 4- [3- ⁇ subst.-amino) -2-hydroxypropoxy] -l ⁇ - thiadiazole compounds with This effect are obtained as racemic compounds which can be separated into optically active isomers by known procedures, for example by forming a salt with an optically active acid, such as optically active tartaric acid, mandelic acid, Cholic acid, O, O-di-p-toluoyl tartaric acid and O, O-dibenzoyl tartaric acid.
  • the invention comprises the compounds having an effect according to the invention in the form of racemic compounds or optically active isomers.
  • R in the general formula is chloroethyl or ethoxy
  • the compounds having the effect according to the invention are generally short-acting beta-adrenergic blocking agents; when R is phenyl, morpholino, piperidino or hydroxypiperidino, the compounds with the effect according to the invention generally have long-acting ⁇ -adrenergic blocking properties and essentially no sympathomimetic effects.
  • the 3-R-4-hydroxy-1,2,5-thiadiazole (A) is treated with epichlorohydrin or epibromohydrin (B).
  • the reaction product (C) can be extracted from the reaction mixture by extraction with etha: be separated.
  • the epihalohydrin is preferably used in excess because of its solvent properties, and the reaction proceeds at room temperature or with heating up to about 90 ° C., the best results being obtained by heating to a temperature between 55 and 70 ° C.
  • the reaction of (A) with (B) is also facilitated by the presence of a trace of a base which serves as a catalyst, with pyridine, piperidine hydrochloride, pyridine or other heterocyclic bases being preferred catalysts.
  • the intermediate (C) is shaken with aqueous alkali.
  • the epoxide (D) is obtained.
  • aqueous sodium or potassium hydroxide at a concentration of about 20% is preferred.
  • Treatment of the epoxide (D) with the amine (E) provides the desired thiadiazole compound (I).
  • the intermediate (C) can be prepared by reacting the starting substance (A) with a haloacetic acid, converting the intermediate into the acid chloride, reacting the acid chloride with diazomethane and reduction, preferably with sodium borohydride.
  • This intermediate product is converted into the thiadiazole (I) according to the procedures described above.
  • thiadiazole starting materials (A) are known compounds or can be prepared from known starting materials.
  • the amine (F) means morpholine, piperidine or hydroxypiperidine.
  • the thiadiazole (Ia) is prepared according to reaction sequence I. The reaction proceeds without pressure at a temperature between about 100 and 150 ° C., preferably between 125 and 135 ° C. Because of its solvent properties, a small excess of the amine (F) is generally used , 3 to 5 moles of amine giving optimal yields.
  • the compounds having the effect according to the invention can be processed according to known procedures for pharmaceutical compositions for oral, rectal or parenteral administration, for example tablets, solutions, suspensions and emulsions. example 1
  • a mixture of 40.2 g (0.21 mol) of 3-chloro-4- (23-epoxypropoxy) -l, 2,5-thiadiazole and 76 g (1.05 mol) of tert-butylamine is used for 2.5 hours heated with stirring to 60 to 70 ° C. Excess te-ct-butylamine is removed in vacuo, leaving 42.4 g of crude product remaining. This is dissolved by shaking with a mixture of diethyl ether and water which contains 2.5 g of sodium hydroxide. The ethereal phase is separated off and the aqueous phase is extracted with several portions of diethyl ether.
  • the following sections describe procedures for the separation of certain racemic products with an effect according to the invention, no attempt being made to assign an absolute configuration to the compounds.
  • the (-) - and (+) - isomers of the separating agents refer to the optical rotation of the (-) - or (+) - parent agent used. All (-) and (+) values given for the connections refer to the actual rotation of the free base, i.e.
  • (+) sign refers to the sign of the free rotation Base (+) - 3-Mo ⁇ holino-2- (3-tat-butylamino-2-hydroxypropoxy-oxy) -l, 2,5-thiadiazole.
  • the above salt (21 g, 0.0323 mol) is shaken with a mixture of 100 ml of water, 14 ml (0.07 mol) of 5N sodium hydroxide solution and 100 ml of diethyl ether.
  • Two further ether extractions (2x50 ml) are carried out , and the combined ethereal extract is extracted once with 30 ml (about 0.04 mol) of 18N hydrochloric acid.
  • the acid layer is extracted once with a small amount of diethyl ether and then with 10 ml (0.05 mol) of 5N Sodium hydroxide solution made basic.
  • the released base is extracted with 100 ml of diethyl ether, followed by two 25 ml portions of ether.
  • the salt is divided between 50 ml of diethyl ether and 50 ml of water, which contains 1 g of sodium carbonate, the layers are separated after vigorous shaking, and the aqueous phase is extracted four times with diethyl ether. The combined ethereal extracts are obtained washed with water and evaporated to give the free base.
  • the infrared spectrum of this sample is identical to that of the racemic hydrogen maleate.
  • An injectable solution is produced by conventional working methods
  • Capsules are manufactured according to conventional methods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation médicamenteuse de l'action immunostimulante et par conséquent antivirale, chez l'homme et chez les animaux présentant une neurorégulation immunitaire à celle de l'homme, de composés de la formule générale (I) où R représente chlore, éthyle, éthoxy, phényle, morpholino, pipéridino ou hydroxypipéridino et où R' représente -C(CH3)3 ou -CH(CH3)2. Le concept d'immunostimulation est défini comme la stimulation simplifiée du système immunitaire en présence d'un antigène étranger. L'action immunostimulante provient d'une part du blocage de l'action inhibitrice du système nerveux sympathique sur le système immunitaire et par ailleurs, du blocage des centres de stress du système nerveux central, notamment du noyau paraventriculaire de l'hypothalamus. Les réactions biochimiques de stimulation du système immunitaire en présence d'un antigène étranger sont renforcées par la suppression de l'action inhibitrice de catécholamines.
EP93907746A 1992-04-22 1993-04-19 Action immunostimulante et par consequent antivirale des composes 4- 3-(aminosubst.)-2-hydroxypropoxy]-1,2,5-thiadiazol Withdrawn EP0591486A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1298/92 1992-04-22
CH129892 1992-04-22
PCT/CH1993/000102 WO1993020814A1 (fr) 1992-04-22 1993-04-19 Action immunostimulante et par consequent antivirale des composes 4-[3-(aminosubst.)-2-hydroxypropoxy]-1,2,5-thiadiazol

Publications (1)

Publication Number Publication Date
EP0591486A1 true EP0591486A1 (fr) 1994-04-13

Family

ID=4207158

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93907746A Withdrawn EP0591486A1 (fr) 1992-04-22 1993-04-19 Action immunostimulante et par consequent antivirale des composes 4- 3-(aminosubst.)-2-hydroxypropoxy]-1,2,5-thiadiazol

Country Status (4)

Country Link
EP (1) EP0591486A1 (fr)
AU (1) AU3886493A (fr)
CA (1) CA2111581A1 (fr)
WO (1) WO1993020814A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009296A1 (fr) * 1994-09-22 1996-03-28 Rational Drug Design Laboratories Derive d'arylthiadiazole et agent antiviral le contenant
US5929247A (en) * 1994-10-24 1999-07-27 Eli Lilly And Company Heterocyclic compounds and their preparation and use
WO1996025163A1 (fr) * 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Traitement de virus de l'herpes
US5661165A (en) * 1996-07-10 1997-08-26 The Dow Chemical Company ((4-phenyl-1,2,5-thiadiazol-3-yl)oxy)methyl ester thiocyanic acid compounds, compositions containing them and their use as antimicrobial and marine antifouling agents
WO1999047507A2 (fr) * 1998-03-19 1999-09-23 Pharmacia & Upjohn Company 1,3,4-thiadiazoles utiles pour le traitement d'infections a cmv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9320814A1 *

Also Published As

Publication number Publication date
WO1993020814A1 (fr) 1993-10-28
CA2111581A1 (fr) 1993-10-28
AU3886493A (en) 1993-11-18

Similar Documents

Publication Publication Date Title
DE3047142C2 (de) Basische 1,7,7-Trimethylbicyclo[2,2,1]heptyläther, Verfahren zur Herstellung derselben und diese enthaltende Arzneimittel
DE2445584C3 (de) L- bzw. DL-2-Methyl-3- (3', 4'-dihydroxyphenyl)-alanin-ester, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2305092C2 (fr)
DD144763A5 (de) Verfahren zur herstellung von phenethanolaminen
EP0074014B1 (fr) 2-(2'-hydroxy-3'-(1,1-diméthylpropylamino)-propoxy)-bêta-propiophénone, ses sels d'addition, procédé de sa préparation et médicament
DE1925956C3 (de) 4- [3-(subst- Amino)-2-hydroxypropoxy] -1,2,5thiadiazolverbindungen und ein diese Verbindungen enthaltendes pharmazeutisches Mittel
EP0591486A1 (fr) Action immunostimulante et par consequent antivirale des composes 4- 3-(aminosubst.)-2-hydroxypropoxy]-1,2,5-thiadiazol
DE2405094A1 (de) 2-aminoindan-abkoemmlinge, deren herstellung und verwendung
DE1915230A1 (de) Hydroxyphenylalkylaminderivate und Verfahren zu deren Herstellung
DE2425767A1 (de) 3-alkyl-9-aminoalkyl-1,2,3,4-tetrahydrocarbazole und ihre verwendung in arzneimitteln
CH640507A5 (en) Process for preparing novel 1-aryloxy-2-hydroxy-3-aminopropanes
EP0109622B1 (fr) Phényl-7-phénoxyméthyl-7-hexahydro-oxazépines-1,4, leur préparation et leur application
DE2003353C3 (de) Phenylisopropylaminoäthanol-Derivate, deren Herstellungsverfahren und Arzneimittel auf deren Basis
EP0462468B1 (fr) 9-amino-2-phenylbicyclo(3.3.1)nonane et 9-amino-2-phenylbicyclo(3.3.1)-non-2-ène et médicaments les contenant
CH643536A5 (de) Alkanolaminderivate.
DE1518334C3 (de) Substituierte Benzylamme und ihre Salze sowie Verfahren zu ihrer Herstellung
DE2139085C3 (de) Halogenierte 4,4-Diphenyl-piperidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
EP0185988B1 (fr) Dérivés du dihydro-10,11 5H-dibenzo[a,d]cycloheptadiène, leur préparation et leur application
EP0462150B1 (fr) Nouvelles aryloxy-alkylamines, leur fabrication et medicaments les contenant
AT304506B (de) Verfahren zur Herstellung neuer Anthracenverbindungen
DE4216942A1 (de) Tetrahydro- und Perhydroisochinolin-Derivate und diese enthaltende therapeutische Mittel
DD209621A5 (de) Verfahren zur herstellung von enantiomeren substituierter phenylazacycloalkane
DE2810482A1 (de) 1-phenyl-2- eckige klammer auf (n-alkyl)-amino eckige klammer zu -propan-1,3-diole, solche enthaltende arzneimittel und verfahren zur herstellung derselben
DE2022790C3 (de) 10-Methyl-5-[ (4-Methylpiperazino)-acetyl J-5,10dihydro-llH-dibenzo [b,e ] [1,4 ] diazepin-11-on, ein Verfahren zu dessen Herstellung sowie dieses enthaltende Arzneimittel
AT351517B (de) Verfahren zur herstellung von neuen aminoalkyl- phenoxyalkansaeuren und deren salzen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19940816

17Q First examination report despatched

Effective date: 19951106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960409

RTI1 Title (correction)

Free format text: IMMUNO-ACTIVATING AND HENCE ANTI-VIRAL EFFECT OF 4- 3-(SUBST.-AMINO)-2-HYDROXYPROPOXY -1,2,5-THIADIAZOLE COMPOUNDS